China
Africa
Explore chapters and articles related to this topic
Sedation and Restraint for Standing Procedures
Published in Michele Barletta, Jane Quandt, Rachel Reed, Equine Anesthesia and Pain Management, 2023
Prior medical therapy included: Non-steroidal anti-inflammatory administration (flunixin meglumine, 1.1 mg/kg IV)Sedation with xylazine (150 mg IV, twice).
Meconium ileus
Published in Mark Davenport, James D. Geiger, Nigel J. Hall, Steven S. Rothenberg, Operative Pediatric Surgery, 2020
Robert J. Vandewalle, Frederick J. Rescorla
Twenty-five neonates had uncomplicated meconium ileus due to intraluminal obstruction of the terminal ileum with concretions of abnormal meconium. The treatment of these patients can be divided into two time periods, 1972–1980 and 1981–1991. Ten infants presented during the first time period, and only two of them were successfully cleared with a diatrizoate meglumine (Gastrografin) enema. The eight remaining infants underwent resection, operative irrigation, and enterostomy formation. A Bishop–Koop stoma was constructed in two infants, and six had a double-barrel (side-by-side) enterostomy. Of the 15 neonates treated during the later time period, eight (53%) were successfully cleared with a Gastrografin enema. The remaining seven infants required laparotomy. Seven were treated with enterotomy and intraoperative irrigation with saline or dilute contrast agent (Hypaque or Gastrografin) and one with irrigation and double-barrel enterostomy.
Clinical Endocrinology of Pregnant Mares
Published in Juan Carlos Gardón, Katy Satué, Biotechnologies Applied to Animal Reproduction, 2020
Daels et al. (1991b) addressed whether flunixin meglumine could prevent luteolysis and maintain pregnancy in mares that were administered endotoxin. Flunixin meglumine, an NSAID cyclo-oxygenase inhibitor interferes with the production of PG. When flunixin meglumine was administered to mares between days 21 and 44 of gestation 10 min before endotoxin administration, endogenous P4 production was maintained and none of the mares lost their pregnancy. In those mares in which flunixin meglumine was administered 1 h after endotoxic insult, systemic P4 fell <2 ng/mL for several days, and pregnancy was lost in one of three mares. When flunixin meglumine was administered 2 h after endotoxic insult, P4 fell <0.5 ng/mL, and all three pregnancies were lost. Likewise, the 12 pregnant mares administered only endotoxin had very low P4 concentrations, and all lost their pregnancies.
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)
Published in Expert Opinion on Therapeutic Patents, 2023
Mariana Verdan, Igor Taveira, Flávia Lima, Fernanda Abreu, Dirlei Nico
For instance, a polymeric nanoparticle was developed in patent WO2015177820 deposited under the PCT agreement, as a vehicle for compounds containing antimony and/or antimonials, such as meglumine antimoniate [126]. The nanoparticle capsule was made of polylactic acid polymer (PLA), and the active principle was trapped in its aqueous core. There was an encapsulation efficiency of 70% of 10 mg of meglumine antimoniate used for the formulation. Under these conditions, the nanoparticle had an average diameter of approximately 309 nm and great uniformity. The Sb release pattern consisted of a fast release of approximately 50% of the active principle in the first 4 hours at 37°C. Then, a slow and gradual release was observed in the following hours until reaching almost 100% release at 24 hours of follow-up [126].
Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives
Published in Journal of Liposome Research, 2021
Jair Téllez, Maria Clara Echeverry, Ibeth Romero, Andrea Guatibonza, Guilherme Santos Ramos, Ana Carolina Borges De Oliveira, Frédéric Frézard, Cynthia Demicheli
Antimonial drugs have also been extensively studied, in association with liposomes, for their efficacy in in vivo models (Castro et al. 2014). In vivo studies have shown that liposomes containing meglumine antimoniate reduced the toxicity levels, prolonged the blood circulation time of the drug and enhanced the leishmanicidal effect, even with a single dose regimen (Frézard et al. 2017). However, these studies have been carried out only in Leishmania donovani and Leishmania infantum parasites, which are responsible for the clinical form of visceral leishmaniasis (VL), leaving aside other parasites, such as Leishmania braziliensis and Leishmania panamensis widely known as main aetiological agents of mucocutaneous (MCL) and cutaneous (CL) leishmaniases in the New World.
Safety profile of meglumine antimoniate intralesional infiltration for cutaneous leishmaniasis
Published in Expert Review of Anti-infective Therapy, 2020
Herbert J. Fernandes, Rosiana E. da Silva, Dario B. Ramalho, Marta G. Aguiar, Josiane N. Silveira, Gláucia Cota
Because of the hypothetical increase in the risk of late mucosal recurrence after local therapies for CL caused by L. brazilienzis, MA-IL therapy has been used for several years in Brazil only in few referral centers. Recently, the paradigm of parenteral therapy for the New World CL succumbed to the lack of evidence of a link between local therapeutic approaches and the risk of late mucosal lesion. In this context, in 2017, meglumine antimoniate intralesional infiltration (MA-IL) was included among the therapeutic alternatives for CL in Brazil in an attempt to reduce morbidity and death possibly related to the available parenteral therapeutic options. In fact, this late complication is also reported after parenteral treatment. Concerning efficacy, evidence of the equivalence between parenteral and intralesional infiltration meglumine antimoniate therapies, including a phase II clinical study performed between 2015 and 2017 at the Leishmaniasis Referral Center of Instituto René Rachou, FIOCRUZ, Minas Gerais, has accumulated in recent years [3,4]. Efficacy data obtained in that study have already been presented (cure rate of 87%, 77–96%) [5]. Currently, the clinical and laboratory monitoring data prospectively collected in that phase II study are the basis of the present analysis.